Drug releasing systems in cardiovascular tissue engineering

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 3, 2009, Pages 422-439

  Spadaccio, Cristiano ^a   Chello, Massimo ^b   Trombetta, Marcella ^b   Rainer, Alberto ^b   Toyoda, Yoshiya ^a   Genovese, Jorge A ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

Author keywords

Cardiovascular graft; Drug delivery; Growth factors; Tissue engineering

Indexed keywords

BIOMATERIAL; DRUG;

ANIMAL; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEM; HUMAN; METHODOLOGY; REVIEW; TISSUE ENGINEERING;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; TISSUE ENGINEERING;

EID: 63049109874     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00532.x     Document Type: Review

References (228)

1. Shinoka T, Shum-Tim D, Ma PX, Tanel RE, Isogai N, Langer R, Vacanti JP, Mayer JE Jr. Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg. 1998 115 : 536 45.
2. Watanabe M, Shin'oka T, Tohyama S, Hibino N, Konuma T, Matsumura G, Kosaka Y, Ishida T, Imai Y, Yamakawa M, Ikada Y, Morita S. Tissue-engineered vascular autograft: inferior vena cava replacement in a dog model. Tissue Eng. 2001 7 : 429 39.
3. Shum-Tim D, Stock U, Hrkach J, Shinoka T, Lien J, Moses MA, Stamp A, Taylor G, Moran AM, Landis W, Langer R, Vacanti JP, Mayer JE Jr. Tissue engineering of autologous aorta using a new biodegradable polymer. Ann Thorac Surg. 1999 68 : 2298 304.
4. Shin'oka T, Matsumura G, Hibino N, Naito Y, Watanabe M, Konuma T, Sakamoto T, Nagatsu M, Kurosawa H. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg. 2005 129 : 1330 8.
5. Hibino N, Shin'oka T, Matsumura G, Ikada Y, Kurosawa H. The tissue-engineered vascular graft using bone marrow without culture. J Thorac Cardiovasc Surg. 2005 129 : 1064 70.
6. Sarkar S, Lee GY, Wong JY, Desai TA. Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials. 2006 27 : 4775 82.
7. Seunarine K, Gadegaard N, Tormen M, Meredith DO, Riehle MO, Wilkinson CD. 3D polymer scaffolds for tissue engineering. Nanomed. 2006 1 : 281 96.
8. Zhang Y, Cheng X, Wang J, Wang Y, Shi B, Huang C, Yang X, Liu T. Novel chitosan/collagen scaffold containing transforming growth factor-beta1 DNA for periodontal tissue engineering. Biochem Biophys Res Commun. 2006 344 : 362 9.
9. Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM. Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. Biomaterials. 2006 27 : 2042 50.
10. Zhang G, Suggs LJ. Matrices and scaffolds for drug delivery in vascular tissue engineering. Adv Drug Deliv Rev. 2007 59 : 360 73.
11. Huang ZMZY, Kotaki M, Ramakrishna S. A review on polymer nanofibers by electro-spinning and their applications in nanocomposites. Compos Sci Technol. 2003 63 : 2223 53.
12. Zhang YZ, Venugopal J, Huang ZM, Lim CT, Ramakrishna S. Characterization of the surface biocompatibility of the electro-spun PCL-collagen nanofibers using fibroblasts. Biomacromolecules. 2005 6 : 2583 9.
13. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresorbable nanofiber-based systems for wound healing and drug delivery: optimization of fabrication parameters. J Biomed Mater Res B Appl Biomater. 2004 70 : 286 96.
14. Kim K, Luu YK, Chang C, Fang D, Hsiao BS, Chu B, Hadjiargyrou M. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release. 2004 98 : 47 56.
15. Zeng J, Xu X, Chen X, Liang Q, Bian X, Yang L, Jing X. Biodegradable electrospun fibers for drug delivery. J Control Release. 2003 92 : 227 31.
16. Kenawy elR, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, Wnek GE. Release of tetracycline hydrochloride from electrospun poly (ethyl-ene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release. 2002 81 : 57 64.
17. Verreck G, Chun I, Rosenblatt J, Peeters J, Dijck AV, Mensch J, Noppe M, Brewster ME. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, non-biodegradable polymer. J Control Release. 2003 92 : 349 60.
18. Luu YK, Kim K, Hsiao BS, Chu B, Hadjiargyrou M. Development of a nanos-tructured DNA delivery scaffold viaelectro-spinning of PLGA and PLA-PEG block copolymers. J Control Release. 2003 89 : 341 53.
19. Tabata Y. Significance of release technology in tissue engineering. Drug Discov Today. 2005 10 : 1639 46.
20. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol. 2001 19 : 1029 34.
21. Zeng F, Lee H, Allen C. Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. Bioconjug Chem. 2006 17 : 399 409.
22. Vehof JW, Fisher JP, Dean D, van der Waerden JP, Spauwen PH, Mikos AG, Jansen JA. Bone formation in transforming growth factor beta-1-coated porous poly(propylene fumarate) scaffolds. J Biomed Mater Res. 2002 60 : 241 51.
23. Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release. 2000 64 : 103 14.
24. Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials. 2000 21 : 2521 7.
25. Whang K, Goldstick TK, Healy KE. A biodegradable polymer scaffold for delivery of osteotropic factors. Biomaterials. 2000 21 : 2545 51.
26. Zilla P, Deutsch M, Meinhart J, Puschmann R, Eberl T, Minar E, Dudczak R, Lugmaier H, Schmidt P, Noszian I. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg. 1994 19 : 540 8.
27. Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, Wang K, Chu B, Li S. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci USA. 2007 104 : 11915 20.
28. Cortes-Morichetti M, Frati G, Schussler O, Van Huyen JP, Lauret E, Genovese JA, Carpentier AF, Chachques JC. Association between a cell-seeded collagen matrix and cellular cardiomyoplasty for myocardial support and regeneration. Tissue Eng. 2007 13 : 2681 7.
29. Chachques JC, Trainini JC, Lago N, Masoli OH, Barisani JL, Cortes-Morichetti M, Schussler O, Carpentier A. Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow-up. Cell Transplant. 2007 16 : 927 34.
30. Chachques JC, Trainini JC, Lago N, Cortes- Morichetti M, Schussler O, Carpentier A. Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM trial): clinical feasibility study. Ann Thorac Surg. 2008 85 : 901 8.
31. Huang NF, Yu J, Sievers R, Li S, Lee RJ. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng. 2005 11 : 1860 6.
32. Philp D, Chen SS, Fitzgerald W, Orenstein J, Margolis L, Kleinman HK. Complex extracellular matrices promote tissue-specific stem cell differentiation. Stem Cells. 2005 23 : 288 96.
33. Dai W, Wold LE, Dow JS, Kloner RA. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol. 2005 46 : 714 9.
34. Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004 10 : 403 9.
35. Remuzzi A, Mantero S, Colombo M, Morigi M, Binda E, Camozzi D, Imberti B. Vascular smooth muscle cells on hyaluronic acid: culture and mechanical characterization of an engineered vascular construct. Tissue Eng. 2004 10 : 699 710.
36. Badylak S, Liang A, Record R, Tullius R, Hodde J. Endothelial cell adherence to small intestinal submucosa: an acellular bioscaffold. Biomaterials. 1999 20 : 2257 63.
37. Schaner PJ, Martin ND, Tulenko TN, Shapiro IM, Tarola NA, Leichter RF, Carabasi RA, Dimuzio PJ. Decellularized vein as a potential scaffold for vascular tissue engineering. J Vasc Surg. 2004 40 : 146 53.
38. Gaspardone A, Versaci F. Coronary stenting and inflammation. Am J Cardiol. 2005 96 : 65L 70L.
39. Versaci F, Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis. 2004 15 : 307 11.
40. Patil SD, Papadimitrakopoulos F, Burgess DJ. Dexamethasone-loaded poly (lactic-co-glycolic) acid microspheres/ poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol Ther. 2004 6 : 887 97.
41. Stankus JJ, Guan J, Wagner WR. Fabrication of biodegradable elastomeric scaffolds with sub-micron morphologies. J Biomed Mater Res A. 2004 70 : 603 14.
42. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A. 2003 65 : 489 97.
43. Radisic M, Euloth M, Yang L, Langer R, Freed LE, Vunjak-Novakovic G. High-density seeding of myocyte cells for cardiac tissue engineering. Biotechnol Bioeng. 2003 82 : 403 14.
44. A.G. Mikos GS, D.E. Ingber, J.P. Vacanti, R. Langer. Prevascularization of porous biodegradable polymers. Biotech Bioeng. 1993 42 : 716 23.
45. K.C. Dee DAP, R Bizios. An introduction to tissue - biomaterial interactions. Hoboken : John Wiley & Sons 2002. pp. 127 47.
46. Carrier RL, Rupnick M, Langer R, Schoen FJ, Freed LE, Vunjak-Novakovic G. Perfusion improves tissue architecture of engineered cardiac muscle. Tissue Eng. 2002 8 : 175 88.
47. Carrier RL, Rupnick M, Langer R, Schoen FJ, Freed LE, Vunjak-Novakovic G. Effects of oxygen on engineered cardiac muscle. Biotechnol Bioeng. 2002 78 : 617 25.
48. Radisic M, Malda J, Epping E, Geng W, Langer R, Vunjak-Novakovic G. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. Biotechnol Bioeng. 2006 93 : 332 43.
49. Radisic M, Park H, Chen F, Salazar-Lazzaro JE, Wang Y, Dennis R, Langer R, Freed LE, Vunjak-Novakovic G. Bio-mimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. Tissue Eng. 2006 12 : 2077 91.
50. Radisic M, Park H, Gerecht S, Cannizzaro C, Langer R, Vunjak-Novakovic G. Biomimetic approach to cardiac tissue engineering. Philos Trans R Soc B Biol Sci. 2007 362 : 1357 68.
51. Zimmermann WH, Fink C, Kralisch D, Remmers U, Weil J, Eschenhagen T. Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol Bioeng. 2000 68 : 106 14.
52. Ennett AB, Mooney DJ. Tissue engineering strategies for in vivo neovascularization. Expert Opin Biol Ther. 2002 2 : 805 18.
53. Lee H, Cusick RA, Browne F, Ho Kim T, Ma PX, Utsunomiya H, Langer R, Vacanti JP. Local delivery of basic fibroblast growth factor increases both angiogenesis and engraftment of hepatocytes in tissue-engineered polymer devices. Trans -plantation. 2002 73 : 1589 93.
54. Mooney DJ, Kaufmann PM, Sano K, McNamara KM, Vacanti JP, Langer R. Transplantation of hepatocytes using porous, biodegradable sponges. Transplant Proc. 1994 26 : 3425 6.
55. Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol. 2003 12 : 295 310.
56. Xu C, Inai R, Kotaki M, Ramakrishna S. Electrospun nanofiber fabrication as synthetic extracellular matrix and its potential for vascular tissue engineering. Tissue Eng. 2004 10 : 1160 8.
57. Stankus JJ, Soletti L, Fujimoto K, Hong Y, Vorp DA, Wagner WR. Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials. 2007 28 : 2738 46.
58. Soletti L, Nieponice A, Guan J, Stankus JJ, Wagner WR, Vorp DA. A seeding device for tissue engineered tubular structures. Biomaterials. 2006 27 : 4863 70.
59. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev. 2001 101 : 1869 79.
60. Matthew IR, Browne RM, Frame JW, Millar BG. Subperiosteal behaviour of alginate and cellulose wound dressing materials. Biomaterials. 1995 16 : 275 8.
61. Gerecht-Nir S, Cohen S, Ziskind A, Itskovitz-Eldor J. Three-dimensional porous alginate scaffolds provide a conducive environment for generation of well-vascularized embryoid bodies from human embryonic stem cells. Biotechnol Bioeng. 2004 88 : 313 20.
62. Bouhadir KH, Lee KY, Alsberg E, Damm KL, Anderson KW, Mooney DJ. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol Prog. 2001 17 : 945 50.
63. Boontheekul T, Kong HJ, Mooney DJ. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials. 2005 26 : 2455 65.
64. Genove E, Shen C, Zhang S, Semino CE. The effect of functionalized self-assembling peptide scaffolds on human aortic endothelial cell function. Biomaterials. 2005 26 : 3341 51.
65. Sieminski AL, Semino CE, Gong H, Kamm RD. Primary sequence of ionic self-assembling peptide gels affects endothelial cell adhesion and capillary morphogenesis. J Biomed Mater Res A. 2008 87 : 494 504.
66. Kedem A, Perets A, Gamlieli-Bonshtein I, Dvir-Ginzberg M, Mizrahi S, Cohen S. Vascular endothelial growth factor-releasing scaffolds enhance vascularization and engraftment of hepatocytes transplanted on liver lobes. Tissue Eng. 2005 11 : 715 22.
67. Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release. 2001 72 : 13 24.
68. Tabata Y. Tissue regeneration based on tissue engineering technology. Congenit Anom. 2004 44 : 111 24.
69. Lee KY, Peters MC, Mooney DJ. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release. 2003 87 : 49 56.
70. Ziegler J, Mayr-Wohlfart U, Kessler S, Breitig D, Gunther KP. Adsorption and release properties of growth factors from biodegradable implants. J Biomed Mater Res. 2002 59 : 422 8.
71. Wei G, Jin Q, Giannobile WV, Ma PX. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release. 2006 112 : 103 10.
72. Hile DD, Pishko MV. Solvent-free protein encapsulation within biodegradable polymer foams. Drug Deliv. 2004 11 : 287 93.
73. Guan J, Stankus JJ, Wagner WR. Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J Control Release. 2007 120 : 70 8.
74. Yoo HS, Lee EA, Yoon JJ, Park TG. Hyaluronic acid modified biodegradable scaffolds for cartilage tissue engineering. Biomaterials. 2005 26 : 1925 33.
75. Yoon JJ, Song SH, Lee DS, Park TG. Immobilization of cell adhesive RGD peptide onto the surface of highly porous biodegradable polymer scaffolds fabricated by a gas foaming/salt leaching method. Biomaterials. 2004 25 : 5613 20.
76. Yoon JJ, Nam YS, Kim JH, Park TG. Surface immobilization of galactose onto aliphatic biodegradable polymers for hepatocyte culture. Biotechnol Bioeng. 2002 78 : 1 10.
77. Park TG. Perfusion culture of hepatocytes within galactose-derivatized biodegradable poly(lactide-co-glycolide) scaffolds prepared by gas foaming of effervescent salts. J Biomed Mater Res. 2002 59 : 127 35.
78. Ishihara M, Sato M, Hattori H, Saito Y, Yura H, Ono K, Masuoka K, Kikuchi M, Fujikawa K, Kurita A. Heparin-carrying polystyrene (HCPS)-bound collagen substratum to immobilize heparin-binding growth factors and to enhance cellular growth. J Biomed Mater Res. 2001 56 : 536 44.
79. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol. 1986 128 : 475 84.
80. Yoon JJ, Chung HJ, Lee HJ, Park TG. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res A. 2006 79 : 934 42.
81. Andreopoulos FM, Persaud I. Delivery of basic fibroblast growth factor (bFGF) from photoresponsive hydrogel scaffolds. Biomaterials. 2006 27 : 2468 76.
82. Cai S, Liu Y, Zheng Shu X, Prestwich GD. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials. 2005 26 : 6054 67.
83. Liu LS, Ng CK, Thompson AY, Poser JW, Spiro RC. Hyaluronate-heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2). J Biomed Mater Res. 2002 62 : 128 35.
84. Boccaccini AR MV. Bioresorbable and bioactive polymer/Bioglass composites with tailored pore structure for tissue engineering applications. Comp Sci Technol. 2003 : 2417 29.
85. Keshaw HFA, Day R. Release of angio-genic growth factors from cells encapsulated in alginate beads with bioactive glass. Biomaterials. 2005 19 : 4171 9.
86. Day RMBA, Shurey S, Roether JA, Forbes A, Hench LL, Gabe SM. Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. Biomaterials. 2004 : 5857 66.
87. Day R, Maquet V, Boccaccini AR, Robert Jerome R, Alastair Forbes A. In vitro and in vivo analysis of macroporous biodegradable poly(D,L-lactide-co- glycolide) scaffolds containing bioactive glass. J Biomed Mater Res A. 2005 75 : 778 87.
88. Leu A, Leach JK. Proangiogenic potential of a collagen/bioactive glass substrate. Pharm Res. 2008 25 : 1222 9.
89. Yoon JJ, Kim JH, Park TG. Dexamethasone-releasing biodegradable polymer scaffolds fabricated by a gas-foaming/salt-leaching method. Biomaterials. 2003 24 : 2323 9.
90. Tabata Y. Current status of regenerative medical therapy based on drug delivery technology. Reprod Biomed Online. 2008 16 : 70 80.
91. Martin I, Shastri VP, Padera RF, Yang J, Mackay AJ, Langer R, Vunjak-Novakovic G, Freed LE. Selective differentiation of mammalian bone marrow stromal cells cultured on three-dimensional polymer foams. J Biomed Mater Res. 2001 55 : 229 35.
92. Peter SJ, Liang CR, Kim DJ, Widmer MS, Mikos AG. Osteoblastic phenotype of rat marrow stromal cells cultured in the presence of dexamethasone, beta-glycerolphosphate, and L-ascorbic acid. J Cell Biochem. 1998 71 : 55 62.
93. Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release. 2007 117 : 68 79.
94. Galeska I, Kim TK, Patil SD, Bhardwaj U, Chatttopadhyay D, Papadimitrakopoulos F, Burgess DJ. Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels. Aaps J. 2005 7 : E231 40.
95. Koedam JA, Smink JJ, van Buul-Offers SC. Glucocorticoids inhibit vascular endothelial growth factor expression in growth plate chondrocytes. Mol Cell Endocrinol. 2002 197 : 35 44.
96. Luo JC, Chi CW, Lin HY, Chang FY, Lu CL, Chen CY, Lee SD. Dexamethasone inhibits epidermal growth factor-stimulated gastric epithelial cell proliferation. J Pharmacol Exp Ther. 2007 320 : 687 94.
97. Luo JC, Shin VY, Liu ES, Ye YN, Wu WK, So WH, Chang FY, Cho CH. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol. 2004 485 : 275 81.
98. Iwai A, Fujii Y, Kawakami S, Takazawa R, Kageyama Y, Yoshida MA, Kihara K. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol Cell Endocrinol. 2004 226 : 11 7.
99. Elcin AE, Elcin YM. Localized angiogene- sis induced by human vascular endothelial growth factor-activated PLGA sponge. Tissue Eng. 2006 12 : 959 68.
100. Elcin YM, Dixit V, Gitnick G. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif Organs. 2001 25 : 558 65.
101. Linn T, Erb D, Schneider D, Kidszun A, Elcin AE, Bretzel RG, Elcin YM. Polymers for induction of revascularization in the rat fascial flap: application of vascular endothelial growth factor and pancreatic islet cells. Cell Transplant. 2003 12 : 769 78.
102. Gu F, Amsden B, Neufeld R. Sustained delivery of vascular endothelial growth factor with alginate beads. J Control Release. 2004 96 : 463 72.
103. Jung RE, Zwahlen R, Weber FE, Molenberg A, van Lenthe GH, Hammerle CH. Evaluation of an in situ formed synthetic hydrogel as a biodegradable membrane for guided bone regeneration. Clin Oral Implants Res. 2006 17 : 426 33.
104. Weber FE, Eyrich G, Gratz KW, Maly FE, Sailer HF. Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres. Int J Oral Maxillofac Surg. 2002 31 : 60 5.
105. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 2003 107 : 1359 65.
106. Smith MK, Peters MC, Richardson TP, Garbern JC, Mooney DJ. Locally enhanced angiogenesis promotes transplanted cell survival. Tissue Eng. 2004 10 : 63 71.
107. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996 94 : 1074 82.
108. Gu F, Neufeld R, Amsden B. Maintenance of vascular endothelial growth factor and potentially other therapeutic proteins bioactivity during a photo-initiated free radical cross-linking reaction forming biodegradable elastomers. Eur J Pharm Biopharm. 2007 66 : 21 7.
109. Sun Q, Chen RR, Shen Y, Mooney DJ, Rajagopalan S, Grossman PM. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res. 2005 22 : 1110 6.
110. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. Am J Surg. 1998 176 : 80S 2S.
111. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006 116 : 237 48.
112. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation. 2006 114 : 637 44.
113. Silva EA, Mooney DJ. Synthetic extracellular matrices for tissue engineering and regeneration. Curr Top Dev Biol. 2004 64 : 181 205.
114. Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from synthetic extracellular matrices. Nature. 2000 408 : 998 1000.
115. Peters MC, Isenberg BC, Rowley JA, Mooney DJ. Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed. 1998 9 : 1267 78.
116. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost. 2007 5 : 590 8.
117. Dor Y, Djonov V, Keshet E. Making vascular networks in the adult: branching morphogenesis without a roadmap. Trends Cell Biol. 2003 13 : 131 6.
118. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hindlimb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003 9 : 604 13.
119. Klabunde R. Cardiovascular physiology concepts. Lippincott, Williams & Wilkins, Philadelphia 2004. pp. 91 140.
120. Fowlkes JL, Winkler MK. Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev. 2002 13 : 277 87.
121. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005 65 : 550 63.
122. Chen RR, Snow JK, Palmer JP, Lin AS, Duvall CL, Guldberg RE, Mooney DJ. Host immune competence and local ischemia affects the functionality of engineered vasculature. Microcirculation. 2007 14 : 77 88.
123. Peters MC, Polverini PJ, Mooney DJ. Engineering vascular networks in porous polymer matrices. J Biomed Mater Res. 2002 60 : 668 78.
124. Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci USA. 2003 100 : 2357 62.
125. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L, Stiber J, Epstein SE, Unger EF. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol. 2000 35 : 519 26.
126. Greisler HP, Gosselin C, Ren D, Kang SS, Kim DU. Biointeractive polymers and tissue engineered blood vessels. Biomaterials. 1996 17 : 329 36.
127. Gray JL, Kang SS, Zenni GC, Kim DU, Kim PI, Burgess WH, Drohan W, Winkles JA, Haudenschild CC, Greisler HP. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. J Surg Res. 1994 57 : 596 612.
128. Massia SP, Hubbell JA. Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials. J Biomed Mater Res. 1991 25 : 223 42.
129. Conte MS, Choudhury RP, Shirakowa M, Fallon JT, Birinyi LK, Choudhry RP. Endothelial cell seeding fails to attenuate intimal thickening in balloon-injured rabbit arteries. J Vasc Surg. 1995 21 : 413 21.
130. Conklin BS, Richter ER, Kreutziger KL, Zhong DS, Chen C. Development and evaluation of a novel decellularized vascular xenograft. Med Eng Phys. 2002 24 : 173 83.
131. Conklin BS, Wu H, Lin PH, Lumsden AB, Chen C. Basic fibroblast growth factor coating and endothelial cell seeding of a decellularized heparin-coated vascular graft. Artif Organs. 2004 28 : 668 75.
132. Hile DD, Amirpour ML, Akgerman A, Pishko MV. Active growth factor delivery from poly(D,L-lactide-co-glycolide) foams prepared in supercritical CO(2). J Control Release. 2000 66 : 177 85.
133. Desire L, Mysiakine E, Bonnafous D, Couvreur P, Sagodira S, Breton P, Fattal E. Sustained delivery of growth factors from methylidene malonate 2.1.2-based polymers. Biomaterials. 2006 27 : 2609 20.
134. Davis ME, Hsieh PC, Takahashi T, Song Q, Zhang S, Kamm RD, Grodzinsky AJ, Anversa P, Lee RT. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci USA. 2006 103 : 8155 60.
135. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977 265 : 625 6.
136. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990 15 : 1667 87.
137. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med. 1988 318 : 1734 7.
138. Liu MW, Roubin GS, King SB, 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989 79 : 1374 87.
139. Knetsch ML, Aldenhoff YB, Schraven M, Koole LH. Human endothelial cell attachment and proliferation on a novel vascular graft prototype. J Biomed Mater Res A. 2004 71 : 615 24.
140. Edelman ER, Nathan A, Katada M, Gates J, Karnovsky MJ. Perivascular graft heparin delivery using biodegradable polymer wraps. Biomaterials. 2000 21 : 2279 86.
141. Verma S, Marsden PA. NO-eluting polyurethanes-vascular grafts of the future? N Engl J Med. 2005 353 : 730 1.
142. Loscalzo J. NO insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001 88 : 756 62.
143. Jun HW, Taite LJ, West JL. NO-producing polyurethanes. Biomacromolecules. 2005 6 : 838 44.
144. Hrabie JA, Keefer LK. Chemistry of the NO-releasing diazeniumdiolate ("nitroso-hydroxylamine") functional group and its oxygen-substituted derivatives. Chem Rev. 2002 102 : 1135 54.
145. Keefer LK, Nims RW, Davies KM, Wink DA. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as NO donors: convenient NO dosage forms. Methods Enzymol. 1996 268 : 281 93.
146. Taite LJ, Yang P, Jun HW, West JL. NO-releasing polyurethane-PEG copolymer containing the YIGSR peptide promotes endothelialization with decreased platelet adhesion. J Biomed Mater Res B Appl Biomater. 2008 84 : 108 16.
147. Deible CR, Beckman EJ, Russell AJ, Wagner WR. Creating molecular barriers to acute platelet deposition on damaged arteries with reactive polyethylene glycol. J Biomed Mater Res. 1998 41 : 251 6.
148. Gombotz WR, Wang GH, Horbett TA, Hoffman AS. Protein adsorption to poly(ethylene oxide) surfaces. J Biomed Mater Res. 1991 25 : 1547 62.
149. Han DK, Park KD, Hubbell JA, Kim YH. Surface characteristics and biocompatibility of lactide-based poly(ethylene glycol) scaffolds for tissue engineering. J Biomater Sci Polym Ed. 1998 9 : 667 80.
150. Kim S. Nonthrombogenic treatments and strategies. San Diego : Academic Press 1996. pp. 297 308.
151. Park KD, Kim YS, Han DK, Kim YH, Lee EH, Suh H, Choi KS. Bacterial adhesion on PEG modified polyurethane surfaces. Biomaterials. 1998 19 : 851 9.
152. Suggs LJ, West JL, Mikos AG. Platelet adhesion on a bioresorbable poly (propylene fumarate-co-ethylene glycol) copolymer. Biomaterials. 1999 20 : 683 90.
153. Jun HW, West JL. Modification of polyurethaneurea with PEG and YIGSR peptide to enhance endothelialization without platelet adhesion. J Biomed Mater Res B Appl Biomater. 2005 72 : 131 9.
154. Sata MSA, Kunisato A. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002 : 403 9.
155. Kushibiki TTY. Future Direction of Gene Therapy in Tissue Engineering In : Reis NARL, editor. Topics in Tis sue Engineering, 2005. pp. 1 33.
156. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol. 2005 90 : 315 26.
157. Quarck R, Holvoet P. Gene therapy approaches for cardiovascular diseases. Curr Gene Ther. 2004 4 : 207 23.
158. Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE, Dzau VJ. Gene and cell-based therapies for heart disease. FASEB J. 2004 18 : 648 63.
159. Audouy SA, de Leij LF, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res. 2002 19 : 1599 605.
160. Voinea M, Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med. 2002 6 : 465 74.
161. Pedroso de Lima MC, Neves S, Filipe A, Duzgunes N, Simoes S. Cationic liposomes for gene delivery: from biophysics to biological applications. Curr Med Chem. 2003 10 : 1221 31.
162. Nah JW, Yu L, Han SO, Ahn CH, Kim SW. Artery wall binding peptide-poly(ethylene glycol)-grafted-poly(L-lysine)-based gene delivery to artery wall cells. J Control Release. 2002 78 : 273 84.
163. Lee H, Jeong JH, Park TG. PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J Control Release. 2002 79 : 283 91.
164. Molas M, Bartrons R, Perales JC. Single-stranded DNA condensed with poly-L-lysine results in nanometric particles that are significantly smaller, more stable in physiological ionic strength fluids and afford higher efficiency of gene delivery than their double-stranded counterparts. Biochim Biophys Acta. 2002 1572 : 37 44.
165. Jeon E, Kim HD, Kim JS. Pluronic-grafted poly-(L)-lysine as a new synthetic gene carrier. J Biomed Mater Res A. 2003 66 : 854 9.
166. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res. 1999 16 : 1273 9.
167. Marschall P, Malik N, Larin Z. Transfer of YACs up to 2.3 Mb intact into human cells with polyethylenimine. Gene Ther. 1999 6 : 1634 7.
168. Campeau P, Chapdelaine P, Seigneurin-Venin S, Massie B, Tremblay JP. Transfection of large plasmids in primary human myoblasts. Gene Ther. 2001 8 : 1387 94.
169. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995 92 : 7297 301.
170. Gosselin MA, Guo W, Lee RJ. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug Chem. 2001 12 : 989 94.
171. Ferrari S, Moro E, Pettenazzo A, Behr JP, Zacchello F, Scarpa M. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther. 1997 4 : 1100 6.
172. Coll JL, Chollet P, Brambilla E, Desplanques D, Behr JP, Favrot M. In vivo delivery to tumors of DNA complexed with linear polyethylenimine. Hum Gene Ther. 1999 10 : 1659 66.
173. Wightman L, Kircheis R, Rossler V, Carotta S, Ruzicka R, Kursa M, Wagner E. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J Gene Med. 2001 3 : 362 72.
174. Brunner S, Furtbauer E, Sauer T, Kursa M, Wagner E. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol Ther. 2002 5 : 80 6.
175. Rainov NG, Kramm CM. Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr Gene Ther. 2001 1 : 367 83.
176. Pooga M, Langel U. Targeting of cancer-related proteins with PNA oligomers. Curr Cancer Drug Targets. 2001 1 : 231 9.
177. Gosselin MA, Lee RJ. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotechnol Annu Rev. 2002 8 : 103 31.
178. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med. 2003 9 : 135 9.
179. Mir LM, Moller PH, Andre F, Gehl J. Electric pulse-mediated gene delivery to various animal tissues. Adv Genet. 2005 54 : 83 114.
180. Murphy WL, Mooney DJ. Controlled delivery of inductive proteins, plasmid DNA and cells from tissue engineering matrices. J Periodontal Res. 1999 34 : 413 9.
181. Shea LD, Smiley E, Bonadio J, Mooney DJ. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol. 1999 17 : 551 4.
182. Wang D, Robinson DR, Kwon GS, Samuel J. Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release. 1999 57 : 9 18.
183. Capan Y, Jiang G, Giovagnoli S, Na KH, DeLuca PP. Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS PharmSciTech. 2003 4 : 1 10.
184. Luo D, Woodrow-Mumford K, Belcheva N, Saltzman WM. Controlled DNA delivery systems. Pharm Res. 1999 16 : 1300 8.
185. Hedley ML. Formulations containing poly (lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opin Biol Ther. 2003 3 : 903 10.
186. Houchin-Ray T, Swift LA, Jang JH, Shea LD. Patterned PLG substrates for localized DNA delivery and directed neurite extension. Biomaterials. 2007 28 : 2603 11.
187. Jang JH, Shea LD. Intramuscular delivery of DNA releasing microspheres: microsphere properties and transgene expression. J Control Release. 2006 112 : 120 8.
188. Jang JH, Bengali Z, Houchin TL, Shea LD. Surface adsorption of DNA to tissue engineering scaffolds for efficient gene delivery. J Biomed Mater Res A. 2006 77 : 50 8.
189. Jang JH, Shea LD. Controllable delivery of non-viral DNA from porous scaffolds. J Control Release. 2003 86 : 157 68.
190. Ismail FA, Napaporn J, Hughes JA, Brazeau GA. In situ gel formulations for gene delivery: release and myotoxicity studies. Pharm Dev Technol. 2000 5 : 391 7.
191. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release. 2001 75 : 211 24.
192. Wang J, Zhang PC, Mao HQ, Leong KW. Enhanced gene expression in mouse muscle by sustained release of plasmid DNA using PPE-EA as a carrier. Gene Ther. 2002 9 : 1254 61.
193. Lim YB, Han SO, Kong HU, Lee Y, Park JS, Jeong B, Kim SW. Biodegradable polyester, poly[alpha-(4-aminobutyl)-L-glycolic acid], as a non-toxic gene carrier. Pharm Res. 2000 17 : 811 6.
194. Park JS, Oh YK, Yoon H, Kim JM, Kim CK. In situgelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA. J Biomed Mater Res. 2002 59 : 144 51.
195. Shen H, Goldberg E, Saltzman WM. Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. J Control Release. 2003 86 : 339 48.
196. Megeed Z, Cappello J, Ghandehari H. Controlled release of plasmid DNA from a genetically engineered silk-elastinlike hydrogel. Pharm Res. 2002 19 : 954 9.
197. Perlstein I, Connolly JM, Cui X, Song C, Li Q, Jones PL, Lu Z, DeFelice S, Klugherz B, Wilensky R, Levy RJ. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther. 2003 10 : 1420 8.
198. Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, Nagai Y, Terada M. New delivery system for plas-mid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med. 1999 5 : 707 10.
199. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J Control Release. 2002 80 : 333 43.
200. Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther. 2004 11 : 1205 14.
201. Huang YC, Simmons C, Kaigler D, Rice KG, Mooney DJ. Bone regeneration in a rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for bone morphogenetic protein-4 (BMP-4). Gene Ther. 2005 12 : 418 26.
202. Bonadio J. Tissue engineering via local gene delivery. J Mol Med. 2000 78 : 303 11.
203. Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med. 1999 5 : 753 9.
204. Ikada Y, Tabata Y. Protein release from gelatin matrices. Adv Drug Deliv Rev. 1998 31 : 287 301.
205. Yamamoto M, Tabata Y, Hong L, Miyamoto S, Hashimoto N, Ikada Y. Bone regeneration by transforming growth factor beta1 released from a biodegradable hydrogel. J Control Release. 2000 64 : 133 42.
206. Mullen PM, Lollo CP, Phan QC, Amini A, Banaszczyk MG, Fabrycki JM, Wu D, Carlo AT, Pezzoli P, Coffin CC, Carlo DJ. Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo. Biochim Biophys Acta. 2000 1523 : 103 10.
207. Park S, Healy KE. Nanoparticulate DNA packaging using terpolymers of poly(lysine-g-(lactide-b-ethylene glycol)). Bioconjug Chem. 2003 14 : 311 9.
208. Moret I, Esteban Peris J, Guillem VM, Benet M, Revert F, Dasi F, Crespo A, Alino SF. Stability of PEI-DNA and DOTAP-DNA complexes: effect of alkaline pH, heparin and serum. J Control Release. 2001 76 : 169 81.
209. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation. 2005 112 : 173 7.
210. Kofidis T, de Bruin JL, Hoyt G, Lebl DR, Tanaka M, Yamane T, Chang CP, Robbins RC. Injectable bioartificial myocardial tissue for large-scale intramural cell transfer and functional recovery of injured heart muscle. J Thorac Cardiovasc Surg. 2004 128 : 571 8.
211. Cummings CL, Gawlitta D, Nerem RM, Stegemann JP. Properties of engineered vascular constructs made from collagen, fibrin, and collagen-fibrin mixtures. Biomaterials. 2004 25 : 3699 706.
212. Levenberg S, Huang NF, Lavik E, Rogers AB, Itskovitz-Eldor J, Langer R. Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci USA. 2003 100 : 12741 6.
213. He W, Ma Z, Teo WE, Dong YX, Robless PA, Lim TC, Ramakrishna S. Tubular nanofiber scaffolds for tissue engineered small-diameter vascular grafts. J Biomed Mater Res A. 2008.
214. Niklason LE, Gao J, Abbott WM, Hirschi KK, Houser S, Marini R, Langer R. Functional arteries grown in vitro. Science. 1999 284 : 489 93.
215. Pankajakshan D, Krishnan VK, Krishnan LK. Vascular tissue generation in response to signaling molecules integrated with a novel poly(epsilon- caprolactone)-fibrin hybrid scaffold. J Tissue Eng Regen Med. 2007 1 : 389 97.
216. Williamson MR, Black R, Kielty C. PCL-PU composite vascular scaffold production for vascular tissue engineering: attachment, proliferation and bioactivity of human vascular endothelial cells. Biomaterials. 2006 27 : 3608 16.
217. Davis ME, Motion JP, Narmoneva DA, Takahashi T, Hakuno D, Kamm RD, Zhang S, Lee RT. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation. 2005 111 : 442 50.
218. Motlagh D, Allen J, Hoshi R, Yang J, Lui K, Ameer G. Hemocompatibility evaluation of poly(diol citrate) in vitro for vascular tissue engineering. J Biomed Mater Res A. 2007 82 : 907 16.
219. Yang J, Webb AR, Pickerill SJ, Hageman G, Ameer GA. Synthesis and evaluation of poly(diol citrate) biodegradable elastomers. Biomaterials. 2006 27 : 1889 98.
220. Wang Y, Ameer GA, Sheppard BJ, Langer R. A tough biodegradable elastomer. Nat Biotechnol. 2002 20 : 602 6.
221. Day RM, Maquet V, Boccaccini AR, Jerome R, Forbes A. In vitro and in vivo analysis of macroporous biodegradable poly(D,L-lactide-co-glycolide) scaffolds containing bioactive glass. J Biomed Mater Res A. 2005 75 : 778 87.
222. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release. 2001 72 : 101 13.
223. Koch S, Yao C, Grieb G, Prevel P, Noah EM, Steffens GC. Enhancing angiogenesis in collagen matrices by covalent incorporation of VEGF. J Mater Sci Mater Med. 2006 17 : 735 41.
224. Ravin AG, Olbrich KC, Levin LS, Usala AL, Klitzman B. Long- and short-term effects of biological hydrogels on capsule microvascular density around implants in rats. J Biomed Mater Res. 2001 58 : 313 8.
225. Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 2000 65 : 389 402.
226. Thompson JA, Anderson KD, DiPietro JM, Zwiebel JA, Zametta M, Anderson WF, Maciag T. Site-directed neovessel formation in vivo. Science. 1988 241 : 1349 52.
227. Yamamoto M, Ikada Y, Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. J Biomater Sci Polym Ed. 2001 12 : 77 88.
228. Ozeki M, Ishii T, Hirano Y, Tabata Y. Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation. J Drug Target. 2001 9 : 461 71.